Oncology Practice Setting Classification: Considerations for Real-World Evidence

Eric S. Meadows, PhD1; Matthew Reynolds, PhD1; Jenna Collins, MPH1; Mark Guinter, PhD1

¹ Flatiron Health, New York, NY

Background

- Due to variations in treatment utilization and patient characteristics (e.g. disease stage or rarity), practice setting has been considered an important factor in oncology real-world evidence (RWE)
- Standard methodology for classifying oncology practices in the United States (US) has not been established
- We evaluated classification schemes relevant for the conduct of RWE studies

Methods

- Classification schemes associated with the following organizations were reviewed and summarized:
 - American Society for Clinical Oncology (ASCO)¹
 - Commission on Cancer (CoC)²
 - Alliance of Dedicated Cancer Centers (ADCC)³
- Characteristics of the practices within the Flatiron Health Database^A were summarized with respect to size of patient population, participation in clinical trials, and area-level socioeconomic status

Table 1. Three examples of classification schemes for oncology practice setting

ASCO	CoC	ADCC
Academic	ACAD	Member (n=10)
System-owned ^a	NCIP	Others
Physician-owned	NCIN	
	INCP	
	CCCP	
	CCP	
	FCCP	
	HACP	
	VACP	
	PCP	

^aincludes hospital and health system-owned.

Academic categories are shaded purple; community categories are shaded blue.

ACAD, Academic Comprehensive Cancer Program;

NCIP, National Cancer Institute (NCI)-Designated Comprehensive Cancer Center Program;

NCIN, NCI-Designated Network Cancer Program;

INCP, Integrated Network Cancer Program;

CCCP, Comprehensive Community Cancer Program;

CCP, Community Cancer Program;

FCCP, Free Standing Cancer Center Program;

HACP, Hospital Associate Cancer Program;

VACP, Veterans Affairs Cancer Program;

PCP, Pediatric Cancer Program

^AThe US nationwide Flatiron Health EHR-derived de-identified database, ^{4,5} comprises patient-level data originating from ~280 cancer clinics (~800 sites of care) and majority community oncology settings; relative community/academic proportions may vary depending on study cohort.

Similar to academic sites, some community oncology practices have high patient volume and conduct clinical trials. Researchers should not assume community oncology practices are homogeneous.



Scan for abstract and digital poster

Acknowledgments: Darren Johnson, PhD (Flatiron Health, Inc.) provided editorial support and Madeline Morenberg (Flatiron Health, Inc.) provided design support. Data first presented at ISPOR 2024 in Atlanta, GA on May 6, 2024.


Disclosures: This study was sponsored by Flatiron Health, Inc.—an independent member of the Roche Group. During the study period, EM, MR, JC, MG reported employment with Flatiron Health, Inc. and stock ownership in Roche.

Author Contact Info: Eric Meadows, eric.meadows@flatiron.com

Results

- Schemes varied in complexity and design (see Table 1)
- The CoC scheme (10 categories) is simplified for analytic purposes
 - Surveillance, Epidemiology, and End Results (SEER) includes CoC designation as a dichotomous flag (yes/no)⁶
 - Researchers also streamline the CoC scheme. For example:
 - academic, NCI, integrated network, community⁷
 - academic, comprehensive community, community
 - academic, other⁹
- Community sites are heterogeneous (see **Figure 1**)
 - Practice size, clinical trial activity, socioeconomic index
- Some community practices have similarities to academic sites

Figure 1. Characteristics of oncology practices



Conclusions

- Classifying oncology practice settings is nuanced
- Guidance is lacking for researchers to classify facilities
- "Community" sites vary across size, socioeconomics & trial activity
- Consolidation, acquisitions, and affiliations further complicate matters
- RWE scientists should ensure that study cohorts reflect the
- Further research is needed to understand how factors that vary by practice setting might influence treatment patterns and outcomes.

References

- 1. Kirkwood M, et al. JOP 2018. doi:10.1200/JOP.18.00149
- 2. Commission on Cancer. Accessed April 18, 2024.

populations of interest

- nttps://www.facs.org/quality-programs/cancer-programs/commission-on-cancer/coc-accreditation/
- 3. Alliance of Dedicated Cancer Centers. Accessed April 18, 2024. https://adcc.org/
- 4. Ma X, et al. MedRxiv. 2023. doi:10.1101/2020.03.16.20037143
- 5. Birnbaum B, et al. arXiv. 2020. doi:10.48550/arxiv.2001.09765
- 6. Adamo M, et al. 2022. Accessed April 18, 2024 https://seer.cancer.gov/manuals/2023/SPCSM 2023 MainDoc.pdf
- 7. Frosch ZAK, et al. JAMA Netw Open. 2021. doi:10.1001/jamanetworkopen.2021.15675
- 8. Mohiuddin JJ, et al. J Am Coll Surg. 2016; doi:10.1016/j.jamcollsurg.2016.08.541
- 9. Frenkel CH, et al. Laryngoscope Investig Otolaryngol. 2022; doi:10.1002/lio2.95